maximum weight loss tirzepatide surmount trials Tirzepatide's Surmount-4 Trial Reveals Groundbreaking Results SURMOUNT-1: In an RCT, adults

More impressively: 58.6% of people on 12 mg lost at least 25% of their body weight 39.4% lost at least 30% Nearly 1 in 4 lost 35% or more These numbers are higher than what we typically see with currently approved GLP-1-based drugs

Compounding tirzepatide simply to reduce cost or improve convenience is now considered an illegal copy of an approved drug under federal law

Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease, 1842(10), 16931706

This population was the primary focus of the SURMOUNT trials and tends to see the most dramatic absolute weight loss

With full treatment adherence, participants taking oral semaglutide 25 mg daily achieved 16.6% mean weight loss at 64 weeks, compared to 2.7% with placebo

They usually resolve within a week or two